> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Latest Federal Register Notices
- URL: https://www.fdaweb.com/latest-federal-register-notices-201/
- Published: 2018-10-28T12:00:00.000Z
- Updated: 2026-09-15T00:40:58.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5142693

[**Info Collection Extension for REMS Requirements**](https://www.fdaweb.com/info-collection-extension-for-rems-requirements/)  
*Federal Register* notice: FDA seeks comments on an information collection extension entitled “Prescription Drug Product Labeling; Medication Guide Requirements.” 10/26/2018

[**Comment Period Reopened on Sucralfate Guide**](https://www.fdaweb.com/comment-period-reopened-on-sucralfate-guide/)  
*Federal Register* notice: FDA reopens the comment period for a revised draft product-specific guidance on sucralfate that appeared in a 10/20/2017 notice. 10/26/2018

[**Draft Guide on Biopharmaceutics Classification System Biowaivers**](https://www.fdaweb.com/draft-guide-on-biopharmaceutics-classification-system-biowaivers/)  
*Federal Register* notice: FDA makes available a draft guidance entitled “Biopharmaceutics Classification System-Based Biowaivers” that was prepared by the International Council for Harmonization. 10/26/2018

[**Regulatory Review Period Determined for Taltz**](https://www.fdaweb.com/regulatory-review-period-determined-for-taltz/)  
*Federal Register* notice: FDA determines for patent extension-related purposes the regulatory review period for Eli Lilly’s Taltz (ixekizumab). 10/26/2018

[**Drug Development Testicular Toxicity Guide**](https://www.fdaweb.com/drug-development-testicular-toxicity-guide/)  
*Federal Register* notice: FDA makes available a guidance entitled “Testicular Toxicity: Evaluation During Drug Development.” 10/25/2018

[**Draft Guide on Drug Supplier Verification Systems**](https://www.fdaweb.com/draft-guide-on-drug-supplier-verification-systems-2/)  
*Federal Register* notice: FDA makes available a draft guidance entitled “Verification Systems Under the Drug Supply Chain Security Act for Certain Prescription Drugs.” 10/25/2018

[**Priority Voucher Awarded to Leadiant Bioscience**](https://www.fdaweb.com/priority-voucher-awarded-to-leadiant-bioscience/)  
*Federal Register* notice: FDA awards a priority review voucher to Leadiant Bioscience after determining that rare disease drug Revcovi (elapegademase-lvlr) injection meets the award criteria. 10/25/2018

[**Joint Panel to Mull Increasing Naloxone in Communities**](https://www.fdaweb.com/joint-panel-to-mull-increasing-naloxone-in-communities/)  
*Federal Register* notice: FDA announces a 12/17 joint advisory committee meeting to discuss strategies to increase the availability of naloxone products intended for use in communities. 10/24/2018